SCHEMBL1574863

SCHEMBL1574863

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CC(N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)C1

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FAAH O00519 19/20 0.67
MGLL Q99685 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574889 0.93 FAAH (0.59) FAAH
SCHEMBL1575350 0.91 FAAH (0.64) FAAH
SCHEMBL1575395 0.90 FAAH (0.60) FAAH
SCHEMBL1575929 0.90 FAAH (0.60) FAAH
SCHEMBL1575419 0.88 FAAH (0.66) FAAH
SCHEMBL1574981 0.86 FAAH (0.59) FAAH
SCHEMBL1575255 0.86 FAAH (0.56) FAAH
SCHEMBL1575104 0.85 FAAH (0.58) FAAH
SCHEMBL1574927 0.85 FAAH (0.61) FAAH
SCHEMBL1575492 0.84 FAAH (0.59) FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB FAAH 3484/4885MGLL 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.